P2X7 嘌呤能受体：心血管疾病治疗的新兴靶点。
The P2X7 purinergic receptor: An emerging therapeutic target in cardiovascular diseases.
机构信息
Institute of Pharmacy and Pharmacology, University of South China, Hengyang 421001, China.
Institute of Pharmacy and Pharmacology, University of South China, Hengyang 421001, China.
出版信息
Clin Chim Acta. 2018 Apr;479:196-207. doi: 10.1016/j.cca.2018.01.032. Epub 2018 Jan 31.
The P2X7 purinergic receptor, a calcium permeable cationic channel, is activated by extracellular ATP. Most studies show that P2X7 receptor plays an important role in the nervous system diseases, immune response, osteoporosis and cancer. Mounting evidence indicates that P2X7 receptor is also associated with cardiovascular disease. For example, the P2X7 receptor activated by ATP can attenuate myocardial ischemia-reperfusion injury. By contrast, inhibition of P2X7 receptor decreases arrhythmia after myocardial infarction, prolongs cardiac survival after a long term heart transplant, alleviates the dilated cardiomyopathy and the autoimmune myocarditis process. The P2X7 receptor also mitigates vascular diseases including atherosclerosis, hypertension, thrombosis and diabetic retinopathy. This review focuses on the latest research on the role and therapeutic potential of P2X7 receptor in cardiovascular diseases.
P2X7 嘌呤能受体是一种钙通透性阳离子通道，由细胞外 ATP 激活。大多数研究表明，P2X7 受体在神经系统疾病、免疫反应、骨质疏松症和癌症中发挥重要作用。越来越多的证据表明，P2X7 受体也与心血管疾病有关。例如，ATP 激活的 P2X7 受体可减轻心肌缺血再灌注损伤。相比之下，抑制 P2X7 受体可减少心肌梗死后心律失常，延长长期心脏移植后的心脏存活期，减轻扩张型心肌病和自身免疫性心肌炎进程。P2X7 受体还可减轻包括动脉粥样硬化、高血压、血栓形成和糖尿病性视网膜病变在内的血管疾病。本综述重点介绍 P2X7 受体在心血管疾病中的作用和治疗潜力的最新研究进展。
Zotero 插件